ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Advocates Oppose Proposals to Market Drugs After Phase I.

June 9, 2006

BMS Demands Resignation Of Two ImClone Executives

February 8, 2002

NIH Extramural Office Lists Initiatives For Reinvention

January 13, 1995

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

Women’s Health: Treatment to Move Toward Pre-Cancer, Klausner Says

December 5, 1997

Nearly 3,000 certified As Oncology Nurses

January 8, 1988